| Q48564707 | 5th International multidisciplinary course on iron anemia, 31st March-1 April 2017, Florence, Italy |
| Q33848929 | A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia |
| Q57064290 | Anemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy |
| Q90720906 | Anemia of Inflammation with An Emphasis on Chronic Kidney Disease |
| Q37084851 | Anemia prevalence and treatment practice in patients with non-myeloid tumors receiving chemotherapy |
| Q37028832 | Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece |
| Q48365358 | Chemotherapy-related anemia |
| Q92130943 | Clinical aspects of mCRPC management in patients treated with radium-223 |
| Q35594086 | Clinical significance of C-reactive protein levels in predicting responsiveness to iron therapy in patients with inflammatory bowel disease and iron deficiency anemia |
| Q41002692 | Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France. |
| Q42336239 | Critical Role of Iron in Epoetin Alfa Treatment of Chemotherapy-Associated Anemia |
| Q41547046 | Current misconceptions in diagnosis and management of iron deficiency |
| Q38815759 | Dose-Dependent Therapeutic Distinction between Active and Passive Targeting Revealed Using Transferrin-Coated PGMA Nanoparticles. |
| Q28072272 | Effectiveness of Physical, Psychological, Social, and Spiritual Intervention in Breast Cancer Survivors: An Integrative Review |
| Q51049616 | Erythropoiesis stimulating agents and clinical outcomes of invasive breast cancer patients receiving cytotoxic chemotherapy. |
| Q45326017 | Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients. |
| Q28538067 | Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled study |
| Q39642839 | Ferric carboxymaltose-mediated attenuation of Doxorubicin-induced cardiotoxicity in an iron deficiency rat model |
| Q91669215 | Hematopoietic Growth Factors in the Management of Anemia and Febrile Neutropenia |
| Q41496658 | Hemoglobin, alkalic phosphatase, and C-reactive protein predict the outcome in patients with liposarcoma |
| Q38184665 | Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways |
| Q88802150 | Impact of ferric carboxymaltose on the evolution of hemoglobin and ECOG performance status in iron-deficient patients with solid tumors: a 3-month follow-up retrospective study |
| Q48227570 | Impact of preoperative anemia on outcomes in patients undergoing curative resection for gastric cancer: a single-institution retrospective analysis of 2163 Chinese patients |
| Q92966814 | Improving preoperative haemoglobin using a quality improvement approach to treat iron deficiency anaemia |
| Q35898038 | Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations |
| Q39445275 | Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial. |
| Q34459582 | Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy |
| Q38733772 | Intravenous iron therapy for anemic cancer patients: a review of recently published clinical studies |
| Q36147237 | Iron Deficiency Anemia Coexists with Cancer Related Anemia and Adversely Impacts Quality of Life |
| Q48011055 | Iron deficiency beyond erythropoiesis: should we be concerned? |
| Q37429231 | Iron deficiency in cancer patients |
| Q98772439 | Iron deficiency in children at the time of initial neuroblastoma diagnosis |
| Q45807225 | Iron deficiency in patients with solid tumours: prevalence and management in clinical practice. |
| Q36619022 | Iron deficient erythropoiesis might play key role in development of anemia in cancer patients |
| Q59808741 | Iron in the Tumor Microenvironment-Connecting the Dots |
| Q36371665 | Iron metabolism and iron supplementation in cancer patients |
| Q38245887 | Iron sucrose - characteristics, efficacy and regulatory aspects of an established treatment of iron deficiency and iron-deficiency anemia in a broad range of therapeutic areas. |
| Q28088503 | Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral? |
| Q47992730 | Management of anemia and iron deficiency in a cancer center in France |
| Q41282906 | Markers of oxidative/nitrosative stress and inflammation in lung tissue of rats exposed to different intravenous iron compounds |
| Q41125350 | Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study |
| Q37602724 | Perioperative anemia management in colorectal cancer patients: a pragmatic approach |
| Q48164757 | Phase III randomized trial comparing intravenous to oral iron in patients with cancer-related iron deficiency anemia not on erythropoiesis stimulating agents |
| Q48212676 | Position paper on management of iron deficiency in adult cancer patients. |
| Q36523881 | Preoperative mean corpuscular hemoglobin affecting long-term outcomes of hepatectomized patients with hepatocellular carcinoma |
| Q33416891 | Prevalence and possible causes of anemia in the elderly: a cross-sectional analysis of a large European university hospital cohort |
| Q36950488 | Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia |
| Q86931837 | Single measurement of hemoglobin predicts outcome of HCC patients |
| Q90645577 | Splenectomy for breast carcinoma diffusely metastatic to the spleen presenting as severe transfusion-dependent anaemia and thrombocytopaenia |
| Q38133907 | Supportive care during treatment for breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. |
| Q28648176 | Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status |
| Q34798132 | The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study |
| Q38140767 | The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications--a review |
| Q99579003 | Treatment of anemia in cancer patients undergoing chemotherapy with intravenous ferric carboxymaltose without erythropoiesis-stimulating agents |
| Q48237731 | Treatment of anemia in patients with solid tumors receiving chemotherapy in palliative setting: usual practice versus guidelines. |
| Q36471843 | Understanding and exploiting hepcidin as an indicator of anemia due to chronic kidney disease |
| Q39132837 | Use of iron sucrose and red blood cell transfusions in anaemic cancer patients in France (OncoFer study). |
| Q50218004 | Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis. |
| Q54558801 | [Anemia--a short overview]. |
| Q52838800 | [Iron deficiency : Recognition and treatment]. |
| Q53367605 | [Preoperative management of anemia in oncologic surgery]. |